Dihydroergotoxin Methanesulfonate
Dihydroergotoxin Methanesulfonate Brand names, Dihydroergotoxin Methanesulfonate Analogs
- Alkergot
- Circanol
- Co-Dergocrine Mesylate
- Deapril-ST
- Dihydroergotoxin Mesilat
- Dihydroergotoxin Mesylate
- Dihydroergotoxin Methanesulfonate
- Dihydroergotoxine Mesilate
- Dihydroergotoxine Mesylate
- Dihydroergotoxine Methanesulfonate
- Dihydroergotoxine Methanesulphonate
- Ergoloid Mesylates [Usan]
- Gerimal
- Hydergin
- Hydergine
- Hydergine LC
- Hydrogenated Ergot Alkaloids
- Ischelium
- Redergin
- Trigot
Dihydroergotoxin Methanesulfonate Brand Names Mixture
- No information avaliable
Dihydroergotoxin Methanesulfonate Chemical_Formula
C33H45N5O5
Dihydroergotoxin Methanesulfonate RX_link
No information avaliable
Dihydroergotoxin Methanesulfonate fda sheet
Dihydroergotoxin Methanesulfonate msds (material safety sheet)
Dihydroergotoxin Methanesulfonate Synthesis Reference
No information avaliable
Dihydroergotoxin Methanesulfonate Molecular Weight
591.741 g/mol
Dihydroergotoxin Methanesulfonate Melting Point
No information avaliable
Dihydroergotoxin Methanesulfonate H2O Solubility
No information avaliable
Dihydroergotoxin Methanesulfonate State
Solid
Dihydroergotoxin Methanesulfonate LogP
2.615
Dihydroergotoxin Methanesulfonate Dosage Forms
Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet
Dihydroergotoxin Methanesulfonate Indication
For use as an adjunct therapy for patients with dementia
Dihydroergotoxin Methanesulfonate Pharmacology
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Dihydroergotoxin Methanesulfonate Absorption
Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Dihydroergotoxin Methanesulfonate side effects and Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Dihydroergotoxin Methanesulfonate Patient Information
No information avaliable
Dihydroergotoxin Methanesulfonate Organisms Affected
Humans and other mammals
